Biomarkers, Surrogate End Points, and the Acceleration of Drug Development for Cancer Prevention and Treatment
Open Access
- 1 June 2004
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (11), 3881-3884
- https://doi.org/10.1158/1078-0432.ccr-03-0783
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug DevelopmentClinical Cancer Research, 2004
- Colorectal AdenomasClinical Cancer Research, 2004
- Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate CancerClinical Cancer Research, 2004
- Reanalysis of Cancer DrugsClinical Cancer Research, 2004
- Trends in development and approval times for new therapeutics in the United StatesNature Reviews Drug Discovery, 2003
- 99mTc-peptide-peptide nucleic acid probes for imaging oncogene mRNAs in tumoursNuclear Medicine Communications, 2003
- Oncology's trialsNature Reviews Drug Discovery, 2003
- Assessment of epidermal growth factor receptor with 99mTc–ethylenedicysteine–C225 monoclonal antibodyAnti-Cancer Drugs, 2003
- Use of Biomarkers and Surrogate Endpoints in Drug Development and Regulatory Decision Making: Criteria, Validation, StrategiesAnnual Review of Pharmacology and Toxicology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000